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Abstract
Archaea present distinct features from bacteria and eukaryotes, and thus constitute one of the branches of the phylogenetic tree of life.
Members of this domain colonize distinct niches in the human body, arranged in complex communities, especially in the intestines and
the oral cavity. The diversity of archaea within these niches is limited to a few phylotypes, constituted in particular by methane-produc-
ing archaeal organisms. Although they are possibly symbionts, methanogens may play a role in the establishment of mucosal diseases by
favouring the growth of certain bacterial groups.
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Introduction
Members of the domain Archaea are prokaryotes that consti-
tute one of the branches of the phylogenetic tree of life, the
others being the domains Bacteria and Eukarya. Although the
name Archaea was proposed by Woese in 1977 [1], the third
domain of life was only accepted after molecular methods
showed signiﬁcant differences in ribosomal RNAs, ribosomal
proteins and the composition of cell surface between mem-
bers of the Archaea and Bacteria or Eukarya [2,3].
Numerous components of the archaeal informational
processes are more similar to their eukaryotic than bacterial
homologues [4]. For instance, archaeal genomes encode
homologues of nearly all eukaryotic DNA replication pro-
teins, but only one homologue of a bacterial DNA replica-
tion protein [2].
On the other hand, the lipids of archaea are unique to this
domain, being formed by isoprenoid side chains ether-linked
to the glycerol moiety, instead of glycerol ester lipids as
found in bacteria [5,6]. Furthermore, the cell wall of archaea
is fundamentally different from the bacterial cell wall. Studies
on archaeal cell surface structures have revealed a lack of
peptidoglycan [7], although a few archaea may possess cell
envelope polymers formed by pseudomurein, similar to bac-
terial peptidoglycan, whereas Methanosarcina spp. have met-
hanochondroitin, similar to the chondroitin produced by
vertebrates. The cell surface of most archaeal organisms has
a crystalline protein layer (S-layer), often composed of a sin-
gle protein or glycoprotein, which is associated with the
cytoplasmic membrane. By contrast, members of the Ther-
moplasmatales, which live under extreme conditions, do not
possess a cell wall [6,8].
Because archaea lack peptidoglycan, their susceptibility to
antibiotics is quite particular. Methanogenic archaea were
found to be resistant to antibiotics used for for bacteria that
target RNA synthesis and inhibit the synthesis or cross-link-
age of the peptide subunit of murein, such as penicillin, ceph-
alosporin, glycopeptides, and aminoglycosides. Despite their
differences in membrane lipids, archaea are susceptible to
antibiotics that inhibit the lipid cycle in bacteria, such as baci-
tracin, chloramphenicol, lasalocid, and monesin [9].
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Surface appendages play an important role in the spatial
organization of cells, from initial surface attachment to the
development of mature community structures. Very little is
known about the morphology and function of surface
appendages of archaea, but members of this domain have
been frequently detected in mixed communities in aggregates
[10] and complex bioﬁlms [11–14]. Thus, it is conceivable
that these structures may have roles in locally increasing the
concentrations of substrates around the cell [15], movement,
and co-aggregation with other microorganisms or adhesion
to abiotic and biotic surfaces [6,8]. Interestingly, genes
encoding class III signal peptides, similar to those encoding
bacterial type IV pilins, were found in the genomes of several
archaea, indicating that as yet undescribed cell surface struc-
tures, such as archaeal pili, may be present in most members
of this domain [16]. In fact, pili-like structures are involved in
bioﬁlm formation by the thermoacidophilic crenarchaeote
Sulfolobus acidocaldarius [17], and in the aggregation of Meth-
anothermobacter thermautotrophicus with bacteria, conferring
more efﬁcient H2 transfer [18].
Archaea are frequently referred to as ‘extremophiles’,
because of their presence in extreme environments with
respect to temperature, osmotic pressure, salinity, and pH
values [19,20]. This terminology has been shown to be inap-
propriate by further research, as members of this domain
have been detected in a wide range of habitats, including the
mucosal surfaces of mammals.
These organisms could be physiologically classiﬁed into:
methanogens (strict anaerobes that produce methane); halo-
philes (strict aerobes living in highly salty environments); and
thermoacidophiles (aerobes living in hot and acidic environ-
ments).
The domain Archaea is composed of four phyla: the Eur-
yarchaeota, the Crenarchaeota, the Korarchaeota, and the
Nanoarchaeota. The main archaea detected in humans and
animals belong to the phylum Euryarchaeota, which includes
the ﬁve known orders of methanogens (Halobacteriales, Met-
hanobacteriales, Methanosarcinales, Methanomicrobiales, and
Methanococcales) [21]; a sixth order has also been proposed
[22]. Methanogenesis is exclusively related to archaeal organ-
isms [2], and the methanogenic archaea are considered to be
the only biological source of methane [23]. These organisms
participate in the conversion of organic matter, under anaer-
obic conditions, by utilizing the metabolic products of bacte-
ria (i.e. CO2, H2, acetate, and formate) and other methyl
compounds available in the environment, converting them to
methane [21,23].
Human microbiome studies have revealed that archaea
colonize distinct niches in the human body, arranged in com-
plex communities [24–27]. Archaea are mainly found in the
gut [13,14,28–30] and the oral cavity [11,12,31–33]. Overall,
archaeal diversity is limited to a few phylotypes in the human
microbiota (i.e. vagina, intestinal tract, and oral cavity)
[21,34]. Methanobrevibacter smithii is the most prevalent spe-
cies in the gut, followed by Methanosphaera stadtmanae [35],
whereas Methanobrevibacter oralis is the main species in the
oral cavity [12,36]. However, recent molecular approaches
have demonstrated that Methanosarcina, Thermoplasma, mem-
bers of the Crenarchaeota and halophilic archaea are also
found in the gastrointestinal tract [9]. The Halobacteriaceae
family, consisting of aerobic halophiles that require a hypers-
aline environment, was detected at low density as compared
with the methanoarchaeal population in the gut microbiota
[37,38], and the presence of members of this family might be
associated with a high-salt-containing diet.
Most archaea inhabiting human surfaces, such as M. smithii
and M. oralis, obtain energy for growth only by the reduction
of CO2 to methane, and are referred to as obligate CO2-
reducing species [39]. Others, like the genus Methanosphaera,
reduce the methyl group of methanol to methane [34]. Fur-
thermore, members of the genus Methanosarcina obtain
energy for growth by producing methane from dismutation
of the methyl group of methanol and methylamines, but also
by reducing CO2, with H2 or CO as the electron donor, and
by converting acetate to methane and CO2 [39]. In the
mixed communities of the intestinal tract, the resulting meth-
ane is used as a source of carbon and energy by some aero-
bic alpha-proteobacteria and delta-proteobacteria [40,41],
and may be exhaled as methane breath [39].
Archaeal metabolism and microbial interactions
The degradation of polymeric materials such as polysaccha-
rides, proteins, nucleic acids and lipids into CO2 and meth-
ane involves a complex microbial community in which the
metabolic capabilities are combined [42]. The mutual depen-
dence between interacting species can be so extreme that
neither species can function without the activity of its part-
ner, and, together, the partners perform functions that nei-
ther species could perform alone.
Methanogenesis is performed by anaerobic consortia that
degrade biological compounds, including lipids, carbohy-
drates, and proteins [43], as shown in Table 1. Most of the
knowledge on methanogens comes from investigations in
both natural and artiﬁcial methanogenic environments, such
as freshwater sediments and anaerobic reactors. However,
these consortia are also functional in the gastrointestinal
tracts of humans and animals, and possibly in the oral cavity.
This evidence came from studies showing that methane pro-
duced in the digestive tract is absorbed into the bloodstream
and exchanged in the lungs [44]; methane can be detected in
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the breath of approximately one-quarter of the adult human
population [45].
Fermentative bacteria hydrolyse the polymeric substrates
and ferment the hydrolysis products into fatty acids, CO2,
and H2 (Fig. 1). Methanogens obtain energy by reducing CO2
and other simple substrates to methane, with H2 as the
primary electron donor [46]. Therefore, they depend on
other microorganisms that degrade more complex organic
compounds for substrate supply.
In anoxic environments, full degradation of low molecular
weight fatty acids such as butyrate, propionate and acetate
occurs only when the H2 partial pressure is kept very low
[47]. In microbial communities, H2-producing bacteria and
H2-utilizing methanogens sense environmental conditions,
inﬂuencing each other’s metabolism. At high concentrations
of hydrogen, the metabolism of the hydrogen producer is
inhibited, whereas that of the methanogen is stimulated, and
vice versa [46]. It is not only the consumption of H2 and
CO2 by methanogens, but also the activity of other hydro-
genotropic groups, as sulphate reducers and acetogenic bac-
teria, that provides the conditions for the further
degradation of the substrate by the microorganisms involved
in the ﬁrst steps of the food chain. The cooperation between
H2-utilizing microorganisms such as methanogens and H2
producers leads to substrate degradation while keeping the
H2 concentration low [48,49]. Thus, the removal of end-
products by methanogens favours the growth of fermenting
bacteria [50], whereas high partial pressures of H2 would
reduce the fermentation efﬁciency [51], as summarized in
Fig. 1.
The balance among members of a complex microbial com-
munity may also be affected by other existing conditions,
such as nutrient availability and pH and O2 levels. For
instance, when electron acceptors other than CO2 are pres-
ent, such as O2, NO3
–, Fe2+, and SO4
2–, methanogens are
outcompeted by bacteria such as sulphate-reducing bacteria
(SRB), denitrifying bacteria, and iron-reducing bacteria. This
phenomenon probably occurs because these compounds are
better electron acceptors, and their reductions are thermo-
dynamically more favourable than CO2 reduction to methane
[42]. However, it seems that methane-producing organisms
TABLE 1. Production of methane from different classes of
substrate [43]
Component Methanogenic reaction
Lipids C50H90O6 + 24.5H2O ﬁ 34.75CH4 + 15.25CO2
Carbohydrates C6H10O5 + H2O ﬁ 3CH4 + 3CO2
Proteins C16H24O5N4+14.5H2O ﬁ 8.25CH4+3.75CO2+4NH4++4HCO3-
FIG. 1. In the intestine, food particles are degraded by fermentative bacteria, resulting in the production of byproducts such as short-chain fatty
acids (SFA), CO2, and H2. Then, methanogens obtain energy by reducing CO2 to methane, with H2 as the primary electron donor.
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can coexist with SRB at comparable levels of abundance in
the human colon [52] and mouth [33].
Methanogens could also outcompete with homoacetogens,
as the latter can reduce CO2 for energy production. How-
ever, homocetogens do not compete well with methanogens
in many habitats, such as the colon [42], as acetogenesis with
H2 is thermodynamically less favourable than methanogene-
sis. On the other hand, homoacetogens may have advantages
over methanogens, owing to their metabolic versatility, such
as lower sensitivity to O2.
Archaea in humans
As methanogenic archaea are involved in a metabolic cas-
cade, they are usually part of a complex biosystem. Archaea,
bacteria and eukaryotic cells coexist in a symbiotic relation-
ship in human mucosal surfaces, such as the intestine [53]
and the oral cavity [33]. Archaea have been found in the
vaginas of some women with bacterial vaginosis [26], but not
in the amniotic ﬂuid of women in preterm labour [54,55].
Despite the fact that the intestine is the largest immune
organ of the body, containing 80% of the human antibody-
producing cells [56], it harbours at least 500–1000 different
bacterial species [35].
After birth, the oxygenated neonatal gut is ﬁrst colonized
by facultative bacteria. In about 1 week, the oxygen is con-
sumed, favouring the establishment of anaerobic bacteria
[57]. The methanogenic archaeon M. smithii was ﬁrst identi-
ﬁed in 1982 from a human faecal culture [24]. It may be
transiently present in the infant gut [14,58], possibly originat-
ing from the mother’s vaginal microbiota [26]. However, it
may become part of the normal resident microbiota of the
intestines in children older than 27 months [59]. This coloni-
zation pattern seems to have no association with dietary
habits, but rather results from environmental contamination
[9].
Methanogenic archaea can be detected in approximately
25–40% of children and 42–82% of adults [59,60], but its
prevalence may be higher. Indeed, a more recent study
reported that 95.5% of the subjects were colonized by
M. smithii, leading to the suggestion that this organism could
be used as an indicator of faecal contamination in water [14].
Methanogenic archaea can constitute up to 10% of all
anaerobes in the colon of healthy adults [35], and may play a
role as a symbiont in the intestines by preventing the accu-
mulation of bacterial end-products [61]. On the other hand,
a role in pathogenesis for methanogenic archaea has been
suggested. An increase in methane breath has been associ-
ated with malignant or premalignant colonic pathology [29],
inﬂammatory bowel disease [13,62], and constipation [45].
Other studies associated an increased proportion of archaea
with inﬂammatory bowel disease (or Crohn’s disease), irrita-
ble bowel syndrome, colorectal cancer, and diverticulosis
[63,64]. The mechanism underlying these pathologies is still
unclear; disease does not seem to be associated with a par-
ticular pathogen, but rather with a microbial shift towards an
anaerobic consortium, consisting of saccharolytic and
proteolytic strictly anaerobic bacteria, including Clostridium,
Eubacterium, the Bacteroides/Prevotella cluster [65,66], the
terminal-degrading methanogens [13,62], and SRB [65], with
a concomitant reduction in probiotic bacteria. In addition,
methanoarchaea in the intestines may enhance ﬁbre digestion
and thus calorie intake, as shown in a humanized gnotobiotic
mouse model [67]. Thus, colonization by methanoarchaea
may be helpful in malnourished subjects, but harmful in
obesity.
The distribution of the oral microbiota is affected by sev-
eral environmental conditions, including redox potential and
nutrient availability. Early dental bioﬁlm colonizers are mainly
facultative anaerobic saccharolytic bacteria, such as Actinomy-
ces and Streptococcus. These species consume O2 and open
the way to the dominance of strictly anaerobic secondary
fermenters, such as Fusobacterium and Prevotella species. This
microbial succession affects the habitat, with a further drop
in the redox potential and the production of gingival ﬂuid,
which contains complex host molecules that can be
exploited as primary nutrient sources by proteolytic anaer-
obes [68]. Then, strictly anaerobic, proteolytic bacteria as
Porphyromonas gingivalis, Treponema denticola and Tannerella
forsythia outcompete the early colonizers and induce gingival
tissue destruction [69].
Our research group has been investigating a possible
interaction between archaea and bacteria in periodontal dis-
ease. As expected, in the oral cavity, methanogens were
mainly detected in the highly anoxic environment of subgingi-
val bioﬁlm and in infected root canals [36,70]. Under these
conditions, methane-producing archaea would possibly
remove end-products, lowering the concentration of H2 and
possibly favouring fermenters. The presence in the subgingi-
val dental plaque of SRB, which use sulphate as electron
acceptor and thus compete with methanogens in most envi-
ronments, has been previously associated with increased
proportions of the periodontopathogens P. gingivalis, T. for-
sythia, and Treponema denticola [71].
Both SRB and methanogenic archaea are terminal
degraders in complex anaerobic systems. Methanogenic ar-
chaea are also present in higher counts and proportions in
diseased than in healthy sites of aggressive periodontitis
subjects [72], and they coexist with a microbiota formed
by saccharolytic bacteria such as Capnocytophaga sp., Eubac-
terium nodatum, and Streptococcus constellatus, and proteo-
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lytic bacteria such as P. gingivalis and T. forsythia [73].
Recent data (unpublished) demonstrated a positive correla-
tion between the levels of archaea and P. gingivalis
(r = 0.75, p 0.001), as well as T. forsythia (r = 0.65, p 0.01),
in the subgingival bioﬁlm of chronic periodontitis subjects.
These data are shown in Fig. 2. On the other hand, peri-
odontally healthy sites colonized by archaea had lower lev-
els of beneﬁcial species of the genera Actinomyces and
Streptococcus, whereas some putative periodontal pathogen
species were found in signiﬁcantly higher levels and pro-
portions than in sites not colonized by these microorgan-
isms. A positive association between methanogens and
Synergites spp., an anaerobic group of bacteria, which are
mostly not yet cultivable, was also reported [36,74]. Thus,
it seems that methanogenic archaea and SRB coexist in
the oral cavity with periodontal pathogens, and may play a
role as terminal degraders of host components, favouring
a continuous catabolic cascade.
Inﬂammatory diseases in the gut [75] and in the oral cavity
[69] are induced by unbalanced microbial communities, with
a depletion in commensal bacteria and an increase in the
anaerobic consortia, which include true and opportunistic
bacterial pathogens, as well as archaea. By using up hydrogen,
methanogens beneﬁt from bacterial byproducts, but they
provide conditions for the growth of anaerobic fermenting
bacteria, including the more virulent ones [21,52]. Even
though the use of antibiotics targeting bacteria is successful
in limiting the damage promoted by microbial consortia in
the gut and oral cavity [76,77], antibacterial agents probably
disrupt the microbial food chain, limiting H2, and lead to an
increase in the redox potential, thus preventing the survival
of anaerobic terminal degraders, the methanoarchaea. Fur-
thermore, methanogens have the ability to transform heavy
metals, or metalloids, into volatile methylated derivatives,
which are more toxic than the original compounds, increas-
ing tissue damage [21,78].
Members of the domain Archaea form part of the resident
microbiota in humans, and may be involved in the microbial
shifts seen in diseased sites, but the clinical relevance of
archaea remains unknown.
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